My Profile
Edit Profile
My Follows
My Wires
My Drafts
Analytics
Email Preferences
Sign Out
home
most popular
Latest
Buy Hold Sell
Alternatives In Focus
Series
Alternatives in Focus
Buy Hold Sell
Expert Insights
Fund in Focus
Income Series
Listed Series
Livewire Live
Meet The Adviser
Meet The Investor
Outlook Series
Rapid Fire
Reporting Season
Signal or Noise
Success and More Interesting Stuff
The Pitch
The Rules of Investing
Undiscovered Funds
Views from the Top
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Assets
Property
Weekend Report
Contributors
Find Funds
Newsletter
About Livewire
Advertising
Careers
Contact Us
Write a Wire
Notifications
Loading...
Write a wire
Account
My profile
My follows
My wires
My drafts
Analytics
Email preferences
Company
About Livewire
Advertising
Contact us
Sign out
Sign In
Join Free
Latest
Buy Hold Sell
Alternatives In Focus
Series
Alternatives in Focus
Buy Hold Sell
Fund in Focus
Income Series
Livewire Live
Meet The Investor
Rapid Fire
Signal or Noise
Success and More Interesting Stuff
The Pitch
The Rules of Investing
Views from the Top
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Assets
Property
Weekend Report
Find funds
Newsletter
matthijs smith
Latest news and analysis on matthijs smith
August 18, 2015 10:46
Momentum building for Medtech microcap Dorsavi
Canaccord Genuity
Stockbroker
August 18, 2015 10:46
August 13, 2015 17:03
Getting pumped about AirXpanders
Canaccord Genuity
Stockbroker
August 13, 2015 17:03
June 02, 2015 17:15
Impedimed: Getting Significant Recognition In The Medical Community
Canaccord Genuity
Stockbroker
June 02, 2015 17:15
Advertisement
May 19, 2015 10:46
Ground-breaking study may lead to accelerated sales pipeline for Nanosonics
Canaccord Genuity
Stockbroker
May 19, 2015 10:46
April 23, 2014 12:11
QRXPharma just saw its market cap shrink 75% from $120mil to $30mil on the FDA saying 'no', as Matthijs smith warned Livewire yesterday: There is unlikely to...
Livewire Equities
Livewire
April 23, 2014 12:11
5
most
popular
Equities
Decade of excellence: 10 years of outstanding performance for L1 Capital’s Long Short Fund
Chris Conway,
Livewire Markets
Equities
The 7 zombie companies lurking on the ASX 300
Ally Selby,
Livewire Markets
Equities
Buy Hold Sell: The best and worst investment ideas from 5 ASX
sectors
Buy Hold Sell,
Livewire Markets
Education
Warren Buffett’s 25 biggest mistakes – and 4 lessons they teach
Chris Leithner,
Leithner & Company Ltd
view all
Advertisement
